1. |
Incorporating molecular profiling in bladder cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1383/84,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
2. |
Cell transplantation for cardiac disease reviewed |
|
Inpharma Weekly,
Volume &NA;,
Issue 1383/84,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
3. |
Four vaccine manufacturers have been asked by the US HHS*to test their vaccines against coronavirus, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1383/84,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
4. |
Antimigraine drug use declining in Spain |
|
Inpharma Weekly,
Volume &NA;,
Issue 1383/84,
2003,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
5. |
Oral pimecrolimus beneficial in psoriasis and atopic dermatitis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1383/84,
2003,
Page 7-8
RM Poole,
Preview
|
|
摘要:
An oral formulation of the calcineurin inhibitor pimecrolimus [SDZ ASM 981, 'Elidel'] is effective and well tolerated in patients with moderate-to-severe psoriasis and atopic dermatitis, according to results from two multinational studies presented at the 61st Annual Meeting of the American Academy of Dermatology [San Francisco, US; March 2003]. Significant improvements in eczema and psoriasis symptoms were achieved in patients treated with twice-daily oral pimecrolimus doses of 20mg or 30mg, compared with placebo, after 6 weeks of treatment. Oral pimecrolimus was well tolerated, with no evidence of serious organ-specific toxicity observed in either study.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
6. |
Zonisamide enhances weight loss in patients with obesity |
|
Inpharma Weekly,
Volume &NA;,
Issue 1383/84,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
7. |
Minocycline beneficial in Huntington's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1383/84,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
8. |
Topical tacrolimus suitable long-term agent in atopic dermatitis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1383/84,
2003,
Page 11-12
Poole Raewyn,
Preview
|
|
摘要:
The topical immunomodulator tacrolimus ['Protopic'] has been shown to be effective and well tolerated in its approved indication, the second-line treatment of moderate-to-severe atopic dermatitis, in a number of clinical studies. As atopic dermatitis is a chronic condition, the effects of long-term treatment with agents such as tacrolimus are of considerable interest. Results from two studies involving more than 8000 adult and paediatric patients with moderate-to-severe atopic dermatitis, presented at the 61st Annual Meeting of the American Academy of Dermatology (AAD)[San Francisco, US; March 2003], showed that long-term intermittent treatment with topical tacrolimus was effective and well tolerated. In these studies, tacrolimus 0.1% ointment continued to provide improvements in atopic dermatitis over treatment periods of up to 4 years. Furthermore, the long-term adverse events profile was equivalent to that observed in studies of shorter duration. Importantly, the incidence of skin infections was not significantly different from that generally observed in patients with atopic dermatitis, and none of the patients in either study experienced skin atrophy, an adverse event commonly associated with prolonged use of topical corticosteroids. Another study presented at the meeting indicated that topical tacrolimus is also effective and well tolerated in patients with less severe dermatitis.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
9. |
Pergolide effective in children and adolescents with tics |
|
Inpharma Weekly,
Volume &NA;,
Issue 1383/84,
2003,
Page 13-13
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
10. |
Statins: first-line therapy for stroke prevention? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1383/84,
2003,
Page 14-14
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|